Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/55248
Title: A mouse peritonitis model for the study of glycopeptide efficacy in GISA infections
Author: Domenech, Alejandro
Ribes, Sandra
Cabellos Mínguez, Ma. Carmen
Domínguez Luzón, Ma. Ángeles (María Ángeles)
Montero Saez, Abelardo
Liñares Louzao, Josefina
Ariza Cardenal, Javier
Gudiol i Munté, Francesc
Keywords: Infeccions per estafilococs
Antibiòtics
Ratolins (Animals de laboratori)
Medicaments antibacterians
Resistència als medicaments
Peritonitis
Staphylococcal infections
Antibiotics
Mice (Laboratory animals)
Antibacterial agents
Drug resistance
Peritonitis
Issue Date: Dec-2004
Publisher: Mary Ann Liebert, Inc.
Abstract: In recent years, the emergence of Staphylococcus aureus strains with reduced susceptibility to glycopeptides has raised considerable concern. We studied the efficacy of vancomycin and teicoplanin, as well as cloxacillin and cefotaxime, against the infection caused by four S. aureus strains with different glycopeptide and β-lactam susceptibilities (strains A, B, C, and D; MICs for vancomycin of 1, 2, 4, and 8 µg/ml respectively), using a modified model of mouse peritonitis. This optimized model appeared to be straightforward and reproducible, and was able to detect low differences in bacterial killing between antibiotics and also between different S. aureus strains. Bactericidal activities in peritoneal fluid for vancomycin, teicoplanin, cloxacillin, and cefotaxime decreased from -2.98, -2.36, -3.22, and -3.57 log10 cfu/ml, respectively, in infection by strain A (MICs for vancomycin and cloxacillin of 1 and 0.38 µg/ml, respectively) to -1.22, -0.65, -1.04, and +0.24 in peritonitis due to strain D (MICs for vancomycin and cloxacillin of 8 and 1,024 µg/ml). Our data confirm the superiority of β-lactams against methicillin-susceptible S. aureus and show that bactericidal activity of glycopeptides decreases significantly with slight increases in MICs; this finding suggests a reduced efficacy of glycopeptides in the treatment of serious glycopeptide-intermediate S. aureus infections
Note: Reproducció del document publicat a: http://dx.doi.org/10.1089/mdr.2004.10.346
It is part of: Microbial Drug Resistance, 2004, vol. 10, num. 4, p. 346-353
Related resource: http://dx.doi.org/10.1089/mdr.2004.10.346
URI: http://hdl.handle.net/2445/55248
ISSN: 1076-6294
Appears in Collections:Articles publicats en revistes (Patologia i Terapèutica Experimental)
Articles publicats en revistes (Ciències Clíniques)

Files in This Item:
File Description SizeFormat 
532586.pdf204.96 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.